Skip to main content
. Author manuscript; available in PMC: 2022 Nov 7.
Published in final edited form as: J Adolesc Health. 2021 Apr 10;69(4):579–587. doi: 10.1016/j.jadohealth.2021.02.023

Table 2.

Multivariable mixed model showing unadjusted and adjusted risk ratios for HPV vaccine series initiation and completion by study group (control vs. autodial vs. mail/text)

Unadjusted and adjusted risk ratios for vaccine initiation and completion by study arm
Study group Colorado
 New York
% Unadjusted risk ratio Adjusted risk ratioa % Unadjusted risk ratio Adjusted risk ratioa
HPV vaccine initiation
 Control 31.3 reference reference 24.1 Ref Ref
 Autodial 31.1   .99 (.94–1.04)   .99 (.94–1.04) 24.1   .97 (.92–1.01)   .97 (.92–1.01)
 Mail 31.8 1.02 (.97–1.07) 1.02 (.98–1.07) N/A
 Text N/A 24.1 1.00 (.96–1.05) 1.00 (.96–1.05)
HPV vaccine completion
 Control 29.7 reference reference 17.1 Ref Ref
 Autodial 31.1 1.04 (1.004–1.09) 1.04 (1.003–1.09) 16.9   .95 (.90–1.00)   .95 (.90–1.01)
 Mail 30.9 1.04 (.998–1.08) 1.04 (.999–1.08) N/A
 Text N/A 17.9 1.06 (1.00–1.11) 1.05 (1.00–1.11)
a

Bold font indicates statistically significant finding.